Summary
Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2016’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections
- The report reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics and enlists all their major and minor projects
- The report assesses Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Arsanis Biosciences GmbH
ContraFect Corporation
Debiopharm International SA
Sealife PHARMA GMBH
Sumitomo Dainippon Pharma Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Overview 6
Therapeutics Development 7
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 7
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis 8
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Development by Companies 9
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes 10
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Development by Companies 13
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Investigation by Universities/Institutes 14
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 15
Arsanis Biosciences GmbH 15
ContraFect Corporation 16
Debiopharm International SA 17
Sealife PHARMA GMBH 18
Sumitomo Dainippon Pharma Co., Ltd. 19
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ASN-100 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CF-301 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Debio-1450 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SLP-0904 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SLP-0905 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SM-295291 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SM-369926 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules for Bacterial Infections - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
targocil - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Recent Pipeline Updates 40
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 45
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 46
Featured News & Press Releases 46
Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2016 7
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Arsanis Biosciences GmbH, H1 2016 15
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corporation, H1 2016 16
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA , H1 2016 17
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 18
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Therapeutics - Recent Pipeline Updates, H1 2016 40
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H1 2016 44
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H1 2016 45
List of Figures
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2016 7
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Top 10 Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27
